Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zai Lab (ZLAB)
NASDAQ:ZLAB
Holding ZLAB?
Track your performance easily
ZLAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.48 - $36.60
Previous CloseN/A
Volume273.50K
Average Volume (3M)597.11K
Market Cap
$2.72B
Enterprise Value$1.78B
Total Cash (Recent Filing)$83.95M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.58
Next Earnings
Mar 04, 2025EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.78
Shares Outstanding109,428,375
10 Day Avg. Volume622,247
30 Day Avg. Volume597,106
Standard Deviation0.19
R-Squared0.07
Alpha-0.00179
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.89
Price to Cash Flow (P/CF)-22.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue5.00
Enterprise Value/Gross Profit10.41
Enterprise Value/Ebitda-10.57
Forecast
1Y Price Target
$50.33Price Target Upside98.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Zai Lab News
Ownership Overview
1.31% Insiders
18.52% Mutual Funds
0.45% Other Institutional Investors
78.95% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ZLAB FAQ
What was Zai Lab’s price range in the past 12 months?
Zai Lab lowest stock price was $13.48 and its highest was $36.60 in the past 12 months.
What is Zai Lab’s market cap?
Zai Lab’s market cap is $2.72B.
When is Zai Lab’s upcoming earnings report date?
Zai Lab’s upcoming earnings report date is Mar 04, 2025 which is in 45 days.
How were Zai Lab’s earnings last quarter?
Zai Lab released its earnings results on Nov 12, 2024. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.783 by $0.743.
Is Zai Lab overvalued?
According to Wall Street analysts Zai Lab’s price is currently Undervalued.
Does Zai Lab pay dividends?
Zai Lab does not currently pay dividends.
What is Zai Lab’s EPS estimate?
Zai Lab’s EPS estimate is -0.69.
How many shares outstanding does Zai Lab have?
Zai Lab has 109,428,375 shares outstanding.
What happened to Zai Lab’s price movement after its last earnings report?
Zai Lab reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.783. Following the earnings report the stock price went down -6.851%.
Which hedge fund is a major shareholder of Zai Lab?
Currently, no hedge funds are holding shares in ZLAB
---
Zai Lab Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$50.33 (98.31% Upside)
$50.33 (98.31% Upside)
Blogger Sentiment
Bullish
ZLAB Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 812.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $214.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days >0.1%
Last 30 Days ▲ 26.4%
Last 30 Days ▲ 26.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.31%
12-Months-Change
Fundamentals
Return on Equity
-34.98%
Trailing 12-Months
Asset Growth
-5.59%
Trailing 12-Months
Company Description
Zai Lab
Zai Lab Ltd. is a biopharmaceutical company, which engages in the licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need. Its product pipelines include ZL-2306, ZL-2401, FPA144, ETX2514, and ZL-2301. The company was founded by Samantha Ying Du and Marietta Wu in 2014 and is headquartered in Shanghai, China.
---
ZLAB Company Deck
---
ZLAB Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth driven by the successful launch of VYVGART, significant advancements in the pipeline, and a substantial reduction in net loss. While there were some increased R&D expenses, the overall financial health and strategic progress indicate a positive outlook.Read More>---
ZLAB Stock 12 Month Forecast
Average Price Target
$50.33
▲(98.31% Upside)
Technical Analysis
BeiGene
―
I-MAB
―
HUTCHMED
―
Kura Oncology
―
Revolution Medicines
―
Sarepta Therapeutics
―
Best Analysts Covering ZLAB
1 Year
1 Year Success Rate
10/19 ratings generated profit
1 Year Average Return
+2.15%
reiterated a buy rating yesterday
Copying David Li's trades and holding each position for 1 Year would result in 52.63% of your transactions generating a profit, with an average return of +2.15% per trade.
---